You are viewing: UAE In Vitro Diagnostics (IVD) Quality Control Market analysis

The UAE In Vitro Diagnostics (IVD) Quality Control Market was valued at $1.95 Million in 2025 and projected to reach to $2.3 Million by 2030, representing a compound annual growth rate of 3.4%. The UAE IVD Quality Control Market is poised for steady growth as the nation continues to strengthen its healthcare ecosystem and diagnostic capabilities.

UAE In Vitro Diagnostics (IVD) Quality Control Market Trends and Insights

  • The UAE's robust healthcare infrastructure and increasing investment in diagnostic capabilities are driving demand for advanced quality control solutions across clinical laboratories and diagnostic centers.
  • The UAE's strategic position as a regional healthcare hub continues to attract both domestic and international diagnostic service providers seeking reliable quality assurance systems. In 2025, the UAE market reflects steady adoption of IVD quality control technologies, supported by stringent regulatory frameworks and the nation's commitment to healthcare excellence.
  • By 2030, the UAE is expected to see accelerated growth driven by rising laboratory automation, increased prevalence of chronic diseases, and enhanced focus on diagnostic accuracy.
  • The UAE's healthcare sector modernization initiatives and growing demand for point-of-care testing solutions are positioning the market for sustained expansion through the forecast period..

Key Market Statistics

  • CAGR (2025-2030) 3.4% CAGR
  • Market Size, 2025 ~USD 1.95 Million
  • Forecast, 2030 ~USD 2.3 Million
  • Country UAE

UAE In Vitro Diagnostics (IVD) Quality Control Market Overview

Market Valuation :

The UAE IVD Quality Control Market is valued at USD 1.95 million in 2025, with steady growth projected to USD 2.30 million by 2030, reflecting the country's commitment to healthcare excellence.

Growth Trajectory :

Expanding at a CAGR of 3.4% through 2030, the UAE market demonstrates consistent demand for quality control solutions driven by regulatory compliance and diagnostic accuracy requirements.

Healthcare Infrastructure :

UAE's robust healthcare infrastructure and significant investments in diagnostic capabilities are creating strong demand for advanced quality control solutions across clinical laboratories and diagnostic centers.

Regulatory Environment :

Stringent quality standards and regulatory frameworks in the UAE healthcare sector are driving adoption of sophisticated IVD quality control systems among diagnostic facilities and hospitals.

UAE In Vitro Diagnostics (IVD) Quality Control Market Dynamics

  • With increasing investments in medical infrastructure and a focus on achieving international quality standards, diagnostic laboratories and clinical centers are prioritizing advanced quality control solutions to ensure accuracy and compliance.
  • The market's 3.4% CAGR reflects moderate but consistent expansion driven by regulatory requirements and the growing complexity of diagnostic testing.
  • Government initiatives supporting healthcare modernization and the rising prevalence of chronic diseases are expected to sustain demand for quality control systems throughout the forecast period..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • The UAE IVD Quality Control Market is valued at USD 1.95 million in 2025 with a projected value of USD 2.30 million by 2030.
      • The UAE market is growing at a CAGR of 3.4%, reflecting steady adoption of quality control technologies in the region's healthcare sector.
      • The UAE's regulatory environment and healthcare modernization initiatives are key drivers supporting market expansion through 2030.
      • The UAE's position as a regional healthcare hub attracts international diagnostic providers, enhancing competition and innovation in quality control solutions.

      In Vitro Diagnostics (IVD) Quality Control Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MOLECULAR DIAGNOSTICS (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 5.5% from 2025 to 2030
      Largest Segment QUALITY CONTROL PRODUCTS (Product & Service)
      Market Size Base Year (Billions) ~USD 1.65 (2025)
      Revenue Forecast (Billions) ~USD 2.15 (2030)
      Segments Covered Product & Service, Type, Technology, Manufacturer Type, End User

      UAE In Vitro Diagnostics (IVD) Quality Control Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product & Service

      • Data Management Solutions
      • Quality Assurance Services
      • Quality Control Products

      By Type

      • Independent Controls
      • Instrument-Specific Controls
      • Other Controls
      • Serum/Plasma-Based Controls
      • Urine-Based Controls
      • Whole Blood-Based Controls

      By Technology

      • Clinical Chemistry
      • Coagulation & Hemostasis
      • Hematology
      • Immunoassays
      • Microbiology
      • Molecular Diagnostics
      • Other Technologies

      By Manufacturer Type

      • Original Equipment Manufacturer Controls
      • Third-Party Controls

      By End User

      • Academic & Research Institutes
      • Clinical Laboratories
      • Hospitals
      • Other End Users

      Target Audience

      • Diagnostic Laboratory Operators : Laboratory managers and operators need this data to understand quality control investment requirements, regulatory compliance standards, and technology adoption trends in the UAE market.
      • IVD Equipment Manufacturers : Manufacturers require UAE-specific market insights to identify growth opportunities, assess demand for quality control solutions, and develop localized product strategies.
      • Healthcare Facility Administrators : Hospital and clinic administrators need market intelligence to budget for quality control systems, understand best practices, and ensure compliance with UAE healthcare standards.
      • Medical Device Distributors : Distributors and suppliers need detailed market data to evaluate business potential, identify customer segments, and develop effective sales strategies in the UAE region.
      • Healthcare Consultants & Investors : Consultants and investors require comprehensive market analysis to assess investment viability, identify growth trends, and make informed decisions about the UAE healthcare diagnostics sector.

      Key Companies in the UAE In Vitro Diagnostics (IVD) Quality Control Market

      CompanyHQOwnershipStrongest segments
      BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers),
      CEPHEID INC.United StatesPrivate CompanyGeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS),
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products,
      DIASORINItalyPublic CompanyImmunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers,
      UNILABSSwitzerlandPrivate CompanyCore laboratory testing,Medical imaging services,Pathology and centres of excellence,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services,
      THERMO FISHER SCIENTIFIC, INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula),
      LGC LIMITEDSouth KoreaPublic CompanyEthylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
      QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC),
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers,
      BIO-TECHNE CORPORATIONUnited StatesPublic CompanyProtein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays,
      MICROBIX BIOSYSTEMS INC.CanadaPublic CompanyAntigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium,
      GRIFOLS, S.A.SpainPublic CompanyBiopharma (plasma-derived medicines),Diagnostic,Bio Supplies,

      BIOMERIEUX S.A.

      bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

      CEPHEID INC.

      Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.

      IMMUCOR, INC.

      Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.

      DIASORIN

      DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.

      UNILABS

      Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.

      THERMO FISHER SCIENTIFIC, INC.

      Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

      ABBOTT

      Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.

      LGC LIMITED

      LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.

      QUIDELORTHO CORPORATION

      QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.

      DANAHER CORPORATION

      Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.

      SYSMEX CORPORATION

      Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.

      BIO-TECHNE CORPORATION

      Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.

      MICROBIX BIOSYSTEMS INC.

      Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.

      GRIFOLS, S.A.

      Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.

      Reasons to Buy this Report

      • Market-Specific Insights : Gain detailed understanding of the UAE IVD quality control landscape, including local market dynamics, regulatory requirements, and growth drivers specific to the Emirates healthcare sector.
      • Competitive Intelligence : Identify key players, market share distribution, and competitive strategies within the UAE market to inform your business development and partnership decisions.
      • Investment Opportunity Assessment : Evaluate market potential and growth prospects in the UAE with accurate forecasts through 2030, enabling informed investment and expansion decisions in the region.
      • Regulatory Compliance Guidance : Understand UAE-specific regulatory frameworks, quality standards, and compliance requirements essential for successfully launching or scaling IVD quality control solutions.
      • Strategic Market Positioning : Develop targeted go-to-market strategies for the UAE by understanding customer segments, procurement patterns, and healthcare facility requirements in the country.

      Frequently asked questions

      What is the current market size of IVD Quality Control in the UAE?

      The UAE In Vitro Diagnostics Quality Control Market is valued at USD 1.95 million in 2025.

      What is the projected market size for IVD Quality Control in the UAE by 2030?

      The UAE market is projected to reach USD 2.30 million by 2030.

      What is the CAGR for the UAE IVD Quality Control Market?

      The UAE market is expanding at a compound annual growth rate of 3.4% from 2025 to 2030.

      What factors are driving growth in the UAE IVD Quality Control Market?

      Key drivers include the UAE's robust healthcare infrastructure, laboratory automation adoption, stringent regulatory frameworks, and the nation's commitment to diagnostic accuracy and healthcare excellence.

      How does the UAE market compare to global IVD Quality Control trends?

      While the global market grows at 5.5% CAGR, the UAE's 3.4% CAGR reflects a more measured but steady adoption pattern aligned with the region's healthcare modernization priorities.

      RESEARCH METHODOLOGY

      The study involved major activities in estimating the current market size for the global IVD quality controls market.

      Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.

      The four steps involved in estimating the market size are as follows:

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      The following is a breakdown of the primary respondents:

      In Vitro Diagnostics (IVD) Quality Control Market

      Note 1: Others include sales, marketing, and product managers.

      Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:

      In Vitro Diagnostics (IVD) Quality Control Market

      Data Triangulation

      After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.

      Stakeholders

      • Senior Management
      • End Users
      • Finance/Procurement Department
      • R&D Department

      Report Objectives

      • To define, describe, segment, and forecast the global IVD quality controls market by product & service, technology, manufacturer type, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall IVD quality controls market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
      • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
      • To benchmark players within the IVD quality controls market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

      Get the Full In Vitro Diagnostics (IVD) Quality Control Market Report

      Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status